Author:
Ilag Liza L.,Costigan Timothy M.,Deeg Mark A.,Pollom Robyn K.,Chang Curtis L.,Konrad Robert J.,Prince Melvin J.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference19 articles.
1. Eli Lilly and Company. European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe (news release). Indianapolis, IN: Eli Lilly and Company, Boehringer Ingelheim; September 10, 2014.
http://lilly.mediaroom.com/index.php?s=9042&item=137348
. Accessed 18 May 2015.
2. Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2014.
http://www.pmda.go.jp/files/000206818.pdf
. Accessed 10 Dec 2015.
3. US Food and Drug Administration. FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes (news release). December 16, 2015.
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm477734.htm
. Accessed 02 Nov 2016.
4. Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38:2226–33. doi:
10.2337/dc14-2623
.
5. Blevins TC, Dahl D, Rosenstock J, et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab. 2015;17:726–33. doi:
10.1111/dom.12496
.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献